Morbidity of tamoxifen-perceptions of patients and healthcare professionals

Breast

Volumn 11, Issue 4, 2002, Pages 335-339

  Adlard, J W ^a   Campbell, J ^a   Bishop, J M ^a   Dodwell, D J ^a  

^a Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEGESTROL; PRIMROSE OIL; TAMOXIFEN;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DYSPAREUNIA; FEMALE; FEMALE SEXUAL DYSFUNCTION; GENERAL PRACTITIONER; HAIR DISEASE; HEADACHE; HEALTH PRACTITIONER; HOT FLUSH; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MASTALGIA; MEDICAL SPECIALIST; MORBIDITY; NURSE; ONCOLOGY; PATIENT ATTITUDE; PATIENT SELECTION; PERCEPTION; PHYSICIAN; POSTMENOPAUSE; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZATION; SYMPTOMATOLOGY; VAGINA DISEASE; VERTIGO; WEIGHT GAIN;

EID: 0036700138     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.2002.0418     Document Type: Article

References (14)

1. Osborne C K. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609-1618.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomized trials involving 31, 000 recurrences and 24, 000 deaths among 75, 000 women. Lancet 1992; 339: 1-15, 71-85.
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
4. Fisher B, Costantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with nodenegative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479-484.
5. Fisher B, Dignam J, Bryant J. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529-1542.
6. Kristensen B, Ejlertsen B, Dalgaard P et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 1994; 12: 992-997.
7. Bergman L, Beelen MLR, Gallee MPW et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000; 356: 881-887.
8. Nayfield S G, Gorin M B. Tamoxifen-associated eye disease. A review. J Clin Oncol 1996; 14: 1018-1026.
9. Swedish Breast Cancer Cooperative Group. Randomised trial for two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996; 88: 1543-1549.
10. Current Trials Working Party Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996; 88: 1834-1839.
11. Demissie S, Silliman A, Lash T L. Adjuvant Tamoxifen: Predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001; 19: 322-328.
12. Love R R, Cameron L, Connell B L, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991; 151: 1842-1847.
13. Brady MJ, Cella DF, Mo F et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 1997; 15: 974-986.
14. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Br Cancer Res Treat 1999; 55: 189-199.